Q4 Net sales of $93.4 million , up 3% year-over-year Q4 GAAP loss per share of $1.21 , inclusive of a one-time tax asset write down of $40.1 million ; Non-GAAP adjusted EPS of $0.19 , up 37% year-over-year Q4 Operating cash generation of $18.5 million FY2017 revenue guidance set at $355-$360

ALBANY, N.Y. , June 29, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2016 fourth

Net sales of $87.4 million , up 1% year-over-year GAAP earnings per share of $0.02 ; Non-GAAP adjusted EPS of $0.15 , up 25% year-over-year Operating cash generation of $12.4 million FY2016 financial guidance updated   ALBANY, N.Y. , April 07, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a

Clemmer brings more than 25 years of operational, manufacturing, marketing and business development experience in the global healthcare industry

ALBANY, N.Y. , March 29, 2016 (GLOBE NEWSWIRE) -- AngioDynamics  (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2016 third

ALBANY, N.Y. , March 10, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that they have signed an agreement with Merz North America ,

ALBANY, N.Y. , March 07, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,

ALBANY, N.Y. , Feb. 08, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Celerity PICC Tip Confirmation System with Navigation has

Net sales of $89.2 million GAAP loss of $0.01 per share; Non-GAAP adjusted EPS of $0.14 Operating cash generation of $9.6 million ALBANY, N.Y. , Jan. 07, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access,

ALBANY, N.Y. , Jan. 04, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph DeVivo , President and Chief Executive Officer, is

ALBANY, N.Y. , Dec. 28, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2016 second

Completes Resolution of All Outstanding Warning Letters

ALBANY, N.Y. , Nov. 23, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,

ALBANY, N.Y. , Nov. 17, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announces that it has received a letter from the United Stated Food and Drug

ALBANY, N.Y. , Nov. 11, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,

ALBANY, N.Y. , Nov. 09, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that Mark Frost has resigned as Executive Vice President and

ALBANY, N.Y. , Oct. 15, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that the NanoKnife® System has been approved by South

Net sales of $83.7 million GAAP loss of $0.02 per share; Non-GAAP adjusted EPS of $0.11 Operating cash generation of $4.7 million Management provides Q2 outlook and reiterates FY2016 guidance ALBANY, N.Y. , Oct. 08, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of

ALBANY, N.Y. , Oct. 1, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2016 first

ALBANY, N.Y. , Sept. 2, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Mark Frost , Executive Vice President and Chief Financial